<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697162</url>
  </required_header>
  <id_info>
    <org_study_id>GCath-CHZ-01</org_study_id>
    <nct_id>NCT02697162</nct_id>
  </id_info>
  <brief_title>Antiseptic-coated Intermittent Urinary Catheter</brief_title>
  <acronym>GuardianCath</acronym>
  <official_title>Antiseptic-coated Intermittent Urinary Catheter: Efficacy and Feasibility of Neurogenic Bladder Management and Prevention of Catheter-associated Urinary Tract Infections in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Zagreb</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GuardianMed j.d.o.o. Research and development in medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Zagreb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design is a prospective, randomised, double-blind, and interventional. Primary aim of
      the study is to investigate efficacy of antiseptic-coated intermittent hydrophilic urinary
      catheters in prevention and reduction of catheter-associated urinary tract infections in
      children with neurogenic bladder. Secondary aim is to assess feasibility of antiseptic-coated
      intermittent hydrophilic urinary catheters in neurogenic bladder management. Octenidine
      chloride will be used as antiseptic.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of urinary tract infections</measure>
    <time_frame>6 months after start of intervention</time_frame>
    <description>Urinary tract infection is diagnosed when both urinalysis results disclose pyuria and/or bacteriuria and the presence of at least 1000 colony-forming units per mL of a uropathogen cultured from a urine specimen obtained through catheterization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months after start of intervention</time_frame>
    <description>Discomfort during catheterisation will be measured by subjective evaluation on a 10-cm visual analogue scale (VAS), where 0 is 'no discomfort' and 10 is 'worst discomfort imaginable'. Pain, stinging, or resistance will be measured on a four-point scale (for example for pain: 1=no pain; 4=severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>6 months after start of intervention</time_frame>
    <description>Adverse events (AEs) and serious AEs will be recorded by the investigator. The presence of visible bleeding will reported by the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expenses of infection-associated treatment</measure>
    <time_frame>6 months after start of intervention</time_frame>
    <description>Total expenses in diagnostics and treatment of urinary tract infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in health-related quality of life measured by PedsQL 4.0 Generic Core questionnaire</measure>
    <time_frame>6 months after start of intervention</time_frame>
    <description>Improvement is defined by increase in total and subscale scores by more than defined minimally clinical important difference for PedsQL 4.0 Generic Core questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gut flora and catheter-associated infections</measure>
    <time_frame>2 years after start of intervention</time_frame>
    <description>Impact of gut flora composition on incidence of catheter-associated urinary tract infections</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neurogenic Bladder</condition>
  <condition>Catheter-Related Infections</condition>
  <arm_group>
    <arm_group_label>Antiseptic-coated catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrophilic intermittent urinary catheter coated with octenidine chloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrophilic catheter</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hydrophilic intermittent urinary catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Antiseptic-coated catheter</intervention_name>
    <description>Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride</description>
    <arm_group_label>Antiseptic-coated catheter</arm_group_label>
    <other_name>GuardianCath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrophilic catheter</intervention_name>
    <description>Hydrophilic intermittent urinary catheter</description>
    <arm_group_label>Hydrophilic catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octenidine chloride</intervention_name>
    <description>Antiseptic</description>
    <arm_group_label>Antiseptic-coated catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neurogenic bladder

          -  use of intermittent catheterisation for neurogenic bladder management

          -  informed oral and written consent from the child and both parents/legal guardian

        Exclusion Criteria:

          -  Congenital anomalies of urinary tract or genitals

          -  Immunodeficiency

          -  Urinary tract fistula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Slaven Abdovic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Zagreb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Slaven Abdovic, MD, PhD</last_name>
    <phone>+385911144333</phone>
    <email>sabdovic@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luka Grgar</last_name>
    <phone>+385981647518</phone>
    <email>lgrgar@guardianmed.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Slaven Abdovic, MD, PhD</last_name>
      <phone>+385911144333</phone>
      <email>sabdovic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Slaven Abdovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intermittent catheterisation</keyword>
  <keyword>Antiseptic</keyword>
  <keyword>Octenidine chloride</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents, Local</mesh_term>
    <mesh_term>Octenidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

